Skip to main content
M1 Kliniken AG logo

M1 Kliniken AG — Investor Relations & Filings

Ticker · M12 ISIN · DE000A0STSQ8 LEI · 529900W697S31A26WT02 F Human health and social work activities
Open in API
Filings indexed 165 across all filing types
Latest filing 2021-02-19 Annual Report
Country DE Germany
Listing F M12

About M1 Kliniken AG

https://www.m1-kliniken.de/en/index.html

M1 Kliniken AG is a provider of health services in the beauty sector, specializing in aesthetic medicine and plastic surgery. The company operates a chain of specialized medical centers offering a range of treatments, including non-surgical procedures like wrinkle and lip treatments, as well as surgical interventions such as breast corrections. The core of its business model is to provide affordable access to aesthetic treatments while maintaining high quality standards. In addition to its clinical services, the company also offers a portfolio of beauty products.

Recent filings

Filing Released Lang Actions
Konzernabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Annual Report Classification · 100% confidence The document is a comprehensive 'Konzernabschluss' (Consolidated Financial Statement) and 'Lagebericht' (Management Report) for MK-Kliniken AG for the fiscal year 2019. It contains detailed financial tables (Profit and Loss), analysis of business segments, risk reports, and management commentary. It is not an announcement of a report (RPA) nor a simple regulatory filing (RNS), but the full annual financial report for the period. In the context of German accounting, this constitutes the Annual Report (10-K equivalent). FY 2019
2021-02-19 German
M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG AG:
M&A Activity Classification · 99% confidence The document is a news release dated December 15, 2020, announcing a significant corporate transaction: M1 Kliniken AG is disposing of its subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG via a capital increase in kind. This involves the issuance of new shares and a change in shareholding percentage. This type of announcement, detailing a major corporate action involving financing, capital structure change, or investment/disposal, fits best under the 'Capital/Financing Update' category (CAP). It is not a standard periodic report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it explicitly details the mechanics of a capital increase and disposal, CAP is the most precise fit.
2020-12-15 English
M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated December 15, 2020, disclosing a significant corporate transaction: M1 Kliniken AG disposing of its subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG via a capital increase in kind. This involves the transfer of shares, valuation, and changes in shareholding percentages. This type of material, non-public information disclosure, especially when referencing MAR (Market Abuse Regulation) Article 17, typically falls under general regulatory announcements or specific transaction categories. Since the core event is a major transaction involving the transfer of a business unit for shares, it strongly relates to corporate restructuring or M&A activity. However, the provided definitions do not have a specific 'M&A' code that perfectly captures a disposal via share issuance, but 'TAR' is defined as 'Merger Proposals or Takeover Bids'. Given the nature of the transaction (disposal/acquisition of a subsidiary for stock), it is a significant corporate action. Since it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), the most fitting category among the choices for a major corporate transaction announcement that isn't strictly financing (CAP) or a general regulatory filing (RNS) is often related to transactions. Since 'TAR' covers M&A, and this is a disposal/acquisition, it is the closest fit, although it's not a merger/takeover bid. If TAR is too narrow, RNS (Regulatory Filings) is the fallback. Given the specific nature of the transaction (transfer of a subsidiary for shares), it is a significant corporate event announcement. I will classify it as a general Regulatory Filing (RNS) as it is an ad-hoc disclosure under MAR, which is a broad regulatory requirement, and it doesn't fit cleanly into the other specific transaction types like CAP or TAR (which implies a bid/merger). However, upon re-evaluation, the transaction is a disposal/acquisition, which is a form of M&A activity. Since TAR is defined as 'Merger Proposals or Takeover Bids', and this is a disposal/acquisition, it is a related corporate transaction. Given the options, RNS is the safest general regulatory announcement category for MAR disclosures that aren't standard reports. Let's check if it fits 'CAP' (Capital/Financing Update). It involves a capital increase, but the primary driver is the disposal of a subsidiary. I will stick with RNS as the most appropriate catch-all for a MAR-mandated ad-hoc disclosure of a significant corporate transaction that doesn't perfectly match the other specific codes.
2020-12-15 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for M1 Kliniken AG for the fiscal year 2019. It contains detailed balance sheets (Aktiva/Passiva), notes to the financial statements (Anhang), and disclosures regarding accounting methods, equity, and subsidiaries. As it represents the full annual financial reporting package rather than just a summary or an announcement, it is classified as an Annual Report (10-K). FY 2019
2020-12-03 German
M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group
Board/Management Information Classification · 100% confidence The document is a short announcement dated November 30, 2020, disclosing that Mr. Patrick Brenske is joining the Management Board of HAEMATO AG and resigning from the Management Board of M1 Kliniken AG. This explicitly details a change in senior management/board composition. According to the definitions, this falls under 'Board/Management Information' (Code: MANG). The document is short and functions as an immediate disclosure, not a comprehensive report.
2020-11-30 English
M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.
Earnings Release Classification · 98% confidence The document is a short news release dated November 4, 2020, titled 'M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020.' It highlights key performance indicators (KPIs) for the third quarter (Q3-2020), such as the number of treatments, expansion activities (new practice openings), and involvement in COVID-19 testing. This format, focusing on key financial/operational highlights for a specific period (Q3), aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is too brief and summary-focused to be a full Interim Report (IR) or Annual Report (10-K). Since it announces results, it is not a Report Publication Announcement (RPA). 9M 2020
2020-11-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.